Remuzzi G
Department of Transplant Immunology and Innovative Antirejection Therapies, Ospedali Riunit, Bergamo, Mario Negri Institute for Pharmacological Research, Italy.
Am J Kidney Dis. 1998 Feb;31(2):197-212. doi: 10.1053/ajkd.1998.v31.pm9469488.
Long-term acceptance of MHC-incompatible organ allografts without chronic immunosuppressive therapy has been achieved in experimental animals. There are also reports, mainly in liver transplant, of patients who after complete withdrawal of immunosuppressants still have a functioning graft. It has been proposed that organ transplant implies a migratory flux of donor "passenger" leukocytes out of the graft into the recipient tissues or organs, serving to establish a persistent condition of "microchimerism," and being a tolerogenic precursor of chimeric cells. Although there is evidence that the same migratory mechanisms apply to all organ grafts, migration of passenger leukocytes is less in organs other than the liver, such as the kidney and heart. To enhance the acceptance of organs less tolerogenic than the liver, perioperative infusion of donor bone marrow has been attempted to increase the migration of donor leukocytes of bone marrow origin. It has been suggested that such peripheral donor microchimerism is not only associated with long-term acceptance of the organ graft but that it plays an active role in induction and maintenance of unresponsiveness. However, the intimate mechanisms(s) responsible for prolonged organ survival in this setting remains speculative. Experimental evidence that the thymus plays the major role in the development of self-tolerance and is also critical in the induction of acquired tolerance to exogenous antigens has focussed the attention on the intrathymic events that lead to donor-specific unresponsiveness to allograft. Data are available showing that after direct intrathymic injection of donor cells, clonal deletion of maturing host thymocytes occurs and is the major mechanism in the induction of donor-specific tolerance. The central role of the thymus in transplant tolerance is also supported by more recent findings that in mixed allogeneic bone marrow chimeras in mice with a nonmyeloablative conditioning regimen, migration of donor bone marrow-derived dendritic cells to the thymus serves to negatively select newly developing host T cells. Therefore, the peripheral T-cell component would be devoid of alloreactive population. Thus, lifelong intrathymic clonal deletion is the only significant mechanism involved in the maintenance of donor-specific T-cell tolerance that would allow the subsequent vascularized organ from the same donor to survive indefinitely.
在实验动物中,已经实现了在无慢性免疫抑制治疗的情况下长期接受 MHC 不相容的器官同种异体移植。也有报道,主要是在肝移植中,一些患者在完全停用免疫抑制剂后移植器官仍能正常发挥功能。有人提出,器官移植意味着供体“过客”白细胞从移植器官迁移到受体组织或器官中,从而建立一种持续的“微嵌合”状态,并成为嵌合细胞的致耐受性前体。虽然有证据表明相同的迁移机制适用于所有器官移植,但除肝脏外的其他器官,如肾脏和心脏,过客白细胞的迁移较少。为了提高对耐受性低于肝脏的器官的接受度,人们尝试在围手术期输注供体骨髓,以增加骨髓来源的供体白细胞的迁移。有人认为,这种外周供体微嵌合不仅与器官移植的长期接受有关,而且在诱导和维持无反应性方面发挥积极作用。然而,在这种情况下导致器官长期存活的具体机制仍具有推测性。胸腺在自身耐受性发展中起主要作用,并且在诱导对外源抗原的获得性耐受性方面也至关重要,这一实验证据将注意力集中在导致对同种异体移植产生供体特异性无反应性的胸腺内事件上。现有数据表明,在将供体细胞直接注入胸腺后,成熟的宿主胸腺细胞会发生克隆清除,这是诱导供体特异性耐受性的主要机制。胸腺在移植耐受性中的核心作用也得到了最近研究结果的支持,即在采用非清髓性预处理方案的小鼠混合同种异体骨髓嵌合体中,供体骨髓来源的树突状细胞向胸腺的迁移有助于对新发育的宿主 T 细胞进行阴性选择。因此,外周 T 细胞成分将缺乏同种异体反应性群体。因此,终身胸腺内克隆清除是维持供体特异性 T 细胞耐受性的唯一重要机制,这将使来自同一供体的后续血管化器官能够无限期存活。